mustang
bio
announces
data
selected
presentation
american
society
hematology
ash
annual
meeting
worcester
globe
newswire
mustang
bio
mustang
nasdaq
mbio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
today
announced
interim
phase
data
autologous
car
cell
therapy
patients
relapsed
refractory
lymphoma
nhl
selected
poster
presentation
american
society
hematology
ash
annual
meeting
held
virtually
december
developed
collaboration
mustang
fred
hutchinson
cancer
research
center
fred
hutch
abstract
posted
today
ash
website
fred
hutch
reported
four
patients
treated
following
major
revision
cell
manufacturing
process
complete
remissions
observed
two
follicular
lymphoma
patients
one
dose
levels
well
partial
remission
mantle
cell
lymphoma
patient
dose
level
progressive
disease
follicular
lymphoma
patient
dose
level
dose
level
x
cells
kg
dose
level
x
cells
kg
previously
disclosed
responses
seen
patients
treated
prior
cell
process
revision
among
total
patients
reported
abstract
one
occurrence
cytokine
release
syndrome
grade
unexplained
alkaline
phosphatase
elevation
setting
fever
patient
treated
prior
cell
process
revision
occurrences
immune
effector
neurotoxicity
syndrome
grade
toxicity
observed
manuel
litchman
president
chief
executive
officer
mustang
said
pleased
fred
hutch
present
interim
data
ash
ongoing
phase
trial
time
expect
disclose
data
least
eight
total
patients
treated
since
major
cell
process
revision
february
reported
first
patient
treated
trial
revised
manufacturing
process
achieved
complete
response
lowest
starting
dose
additional
data
disclosed
today
indicate
extremely
favorable
safety
profile
evidence
promising
clinical
activity
even
low
dose
levels
look
forward
continuing
progress
car
cell
therapy
program
patients
relapsed
refractory
details
presentation
follows
title
third
generation
targeted
car
therapy
treatment
patients
relapsed
refractory
lymphoma
session
immunotherapies
poster
abstract
date
time
saturday
december
et
presenter
mazyar
shadman
associate
professor
clinical
research
division
fred
hutch
seattle
wa
information
please
visit
ash
annual
meeting
exposition
website
https
meetings
abstracts
lymphoma
nhl
several
forms
nhl
including
follicular
lymphoma
mantle
cell
lymphoma
marginal
zone
lymphoma
lymphoplasmacytic
lymphoma
small
lymphocytic
lymphoma
account
collectively
cases
nhl
types
nhl
incurable
available
therapies
except
allogenic
hematopoietic
stem
cell
transplant
new
cases
nhl
diagnosed
year
united
states
patients
die
annually
due
group
diseases
car
cell
therapy
surface
molecule
plays
role
differentiation
plasma
cells
car
developed
mustang
research
partner
fred
hutchinson
cancer
research
center
fred
hutch
laboratory
oliver
press
brian
till
clinical
research
division
exclusively
licensed
mustang
bio
optimized
car
derived
fully
human
antibody
currently
phase
trial
fred
hutch
lymphoma
patients
additional
information
trial
found
http
using
identifier
mustang
bio
mustang
bio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
mustang
aims
acquire
rights
technologies
licensing
otherwise
acquiring
ownership
interest
fund
research
development
outlicense
bring
technologies
market
mustang
partnered
top
medical
institutions
advance
development
car
therapies
across
multiple
cancers
well
lentiviral
gene
therapy
severe
combined
immunodeficiency
xscid
also
known
bubble
boy
disease
mustang
registered
securities
exchange
act
amended
files
periodic
reports
securities
exchange
commission
sec
mustang
founded
fortress
biotech
nasdaq
fbio
information
visit
statements
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
statements
include
limited
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
value
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
risks
relating
timing
starting
completing
clinical
trials
uncertainties
relating
preclinical
clinical
testing
dependence
suppliers
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
sec
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
required
law
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
company
contacts
jaclyn
jaffe
william
begien
mustang
bio
ir
investor
relations
contact
daniel
ferry
lifesci
advisors
llc
daniel
media
relations
contact
tony
plohoros
degrees
tplohoros
